SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted genetic medicines, today announced the presentation of new data on its first therapeutic candidate from its RedTail platform, CLD-401, at the Society of Immunotherapy for Cancer (SITC) Annual Meeting. CLD-401 is a tumor-tropic oncolytic virus designed to home to metastatic sites after ...

LONGBOAT KEY, FL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Rumble Inc. (NASDAQ: RUM) (“Rumble” or the “Company”), the video-sharing platform and cloud services provider, today announced that it will release financial results for the fiscal quarter ended September 30, 2025 after market close on Wednesday, November 12, 2025. The Company will host a conference call on the same day at 5:00 p.m. Eastern Time. Access to the live webcast and replay of the conference call, along with related earnings release materials, wi ...

Advanced Drones to Enhance Training Against Multinational Forces at Joint Multinational Readiness Center WICHITA, Kan., Oct. 30, 2025 (GLOBE NEWSWIRE) -- AgEagle Aerial Systems Inc. (dba, EagleNXT) (the “Company” or “EagleNXT”) (NYSE: UAVS), a leading provider of advanced drone and aerial imaging solutions, is proud to announce the sale of three eBee VISION drones to the U.S. Army’s 1st Battalion, 4th Infantry Regiment (1-4 IN), stationed at the Joint Multinational Readiness Center (JMRC) in Hohenfels, Germ ...

Core Points - Australian Oilseeds Holdings Limited has regained compliance with Nasdaq's minimum bid price requirement and will transfer its listing to The Nasdaq Capital Market effective October 31, 2025 [1][2][3] - The transfer is not expected to impact trading of the Company's securities, which will continue to trade under the symbols "COOT" for Class A ordinary shares and "COOTW" for warrants [2] - The Nasdaq Capital Market has similar operational standards to the Nasdaq Global Market, requiring companies to meet specific financial and corporate governance criteria for continued listing [2] Company Overview - Australian Oilseeds Holdings Limited is focused on the manufacture and sale of sustainable oilseeds, including non-GMO and organic food-grade oils, targeting the growing oilseeds market [3] - The Company operates the largest cold pressing oil plant in Australia, emphasizing the production of GMO-free conventional and organic oilseeds [3] - The Company aims to eliminate chemicals from its production processes, thereby supplying healthier food ingredients and vegetable oils to customers globally [3]

MATTOON, Ill., Oct. 30, 2025 (GLOBE NEWSWIRE) -- First Mid Bancshares, Inc. (NASDAQ: FMBH) (the “Company”) today announced its financial results for the quarter ended September 30, 2025. Highlights Quarterly net income of $22.5 million, or $0.94 diluted EPSAdjusted quarterly net income* of $23.3 million, or $0.97 diluted EPSNet interest margin tax equivalent* expands to 3.80%, quarterly increase of 8 basis points, helping drive the sixth consecutive quarter of growth in net interest incomeTotal loans of $5. ...

Core Insights - Kojamo plc reported an improvement in occupancy rates, with total revenue and net rental income showing increases during the review period [1][6][12] Financial Performance - Total revenue for Q3 2025 was EUR 113.6 million, a 0.4% increase from EUR 113.2 million in Q3 2024 [5][6] - Net rental income for Q3 2025 was EUR 86.0 million, up 0.3% from EUR 85.7 million in Q3 2024, representing a margin of 75.7% [5][6] - Profit before taxes for Q3 2025 was EUR 32.8 million, down 35.2% from EUR 50.6 million in Q3 2024, influenced by a net loss of EUR 16.4 million from property valuations [5][6] - Funds From Operations (FFO) decreased by 3.3% to EUR 44.1 million in Q3 2025 compared to EUR 45.6 million in Q3 2024 [5][6] Investment and Property Management - Kojamo owned 39,001 rental apartments at the end of the review period, a decrease from 40,973 apartments the previous year [4] - Gross investments in Q3 2025 totaled EUR 13.6 million, representing 12.0% of total revenue, compared to EUR 2.2 million in Q3 2024 [5][6] - The fair value of investment properties was EUR 7.6 billion at the end of the review period, including EUR 41.8 million in properties held for sale [6] Occupancy and Market Conditions - The financial occupancy rate improved to 94.4% during the review period, with a further increase to 96.1% in Q3 2025 [6][13] - The rental market is balancing, with oversupply in the capital region but normalizing conditions in cities like Tampere and Turku [14] Strategic Developments - The company completed the sale of 44 residential properties, comprising 1,944 apartments, using EUR 200 million of the proceeds to repay loans [15] - A share buyback program was initiated, with plans to use up to EUR 75 million for buybacks [15] - A strategy review is underway to update the existing strategy, with further information expected during the financial statements publication [17] Outlook - Kojamo estimates a total revenue increase of 0-2% year-on-year for 2025, with FFO projected to be between EUR 135-141 million, excluding non-recurring costs [8][10]

Core Insights - IMUNON, Inc. has been invited to present its ongoing Phase 3 OVATION 3 clinical trial of IMNN-001 at the IGCS and ESMO Congress 2025, highlighting the therapy's potential in treating advanced ovarian cancer [1][3] Company Overview - IMUNON is a clinical-stage biotechnology company focused on developing innovative treatments using its proprietary TheraPlas technology platform, which enables gene-based delivery of therapeutic proteins [10][11] - The company's lead clinical program, IMNN-001, is a DNA-based immunotherapy targeting advanced ovarian cancer, having completed multiple clinical trials including a Phase 2 trial [11] Clinical Trial Details - The OVATION 3 study is a pivotal Phase 3 trial evaluating the safety and efficacy of IMNN-001 in combination with standard chemotherapy for newly diagnosed advanced ovarian cancer patients [4][5] - The trial has shown promising results from the Phase 2 OVATION 2 study, with a median overall survival (OS) increase of 13 months and a median progression-free survival (PFS) increase of 3 months compared to standard care [5][7] - The study design includes two planned interim analyses and aims for at least 95% statistical power on the primary endpoint of overall survival [5] Treatment Mechanism - IMNN-001 utilizes an interleukin-12 (IL-12) DNA plasmid vector in a nanoparticle delivery system, promoting local production of IL-12 in the tumor microenvironment, which is crucial for inducing anticancer immunity [2][8] - The therapy has demonstrated a significant therapeutic effect, with a hazard ratio (HR) of 0.70 for OS and 0.79 for PFS compared to standard care [5] Market Context - Epithelial ovarian cancer is a significant health concern, with approximately 20,000 new cases annually in the U.S., and a high recurrence rate post-treatment [9] - There is a critical need for therapies that improve overall survival and reduce recurrence rates in patients diagnosed with advanced stages of the disease [9]

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- XWELL, Inc. (Nasdaq: XWEL) (“XWELL” or the “Company”), a leading provider of wellness solutions for people on the go, today announced its partnership with Priority Pass, the world’s leading airport experiences program, is going global. What first launched in North America last year is now being expanded to key international airports across the Middle East and Europe, giving travelers more ways to take care of themselves mid-journey. Through the expanded collaborat ...

MADRID, Spain and CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that its management will participate at the following upcoming events: BIO-EUROPE, November 3-5Location: Viena Congress and Convention Center, Vienna, Austria LSX Investival Showcase Europe 2025, November 17Location: Old Billingsgate, London, United Kingdom Jefferies Global Healthcare Conferenc ...

Financial Position - Evaxion A/S has raised a total of $7.2 million recently, with $4.5 million from an at-the-market offering and $2.7 million from the exercise of investor warrants [2][7] - The company now has sufficient cash to fund its operations and R&D programs into the second half of 2027, extending from the first half of 2027 [1][7] Debt Management - By the end of the second quarter of 2025, Evaxion had cash on hand of $14.7 million and a debt of $9.2 million [4] - The debt was reduced by $4.1 million through a debt-to-equity conversion agreement with the European Investment Bank in July 2025, enhancing the company's equity position [4] Operational Insights - Evaxion expects to incur an operational cash spend of $14 million in 2025 [4] - The recent exercises of investor warrants have decreased the number of outstanding warrants to purchase Evaxion American Depositary Shares (ADSs) by 1.0 million, leaving a total of 2.8 million outstanding warrants [3][7] Company Overview - Evaxion is a clinical-stage TechBio company that utilizes its AI-Immunology™ platform to develop vaccines targeting cancer, bacterial diseases, and viral infections [5] - The company is focused on creating novel personalized vaccines and has a pipeline addressing high unmet medical needs in infectious diseases [5]